NICE

has rejected a breakthrough drug for breast cancer on the grounds that, at £3,000 a month, it’s too expensive. But that is a drop in the ocean next to the gargantuan sums we’ve spent on coronavirus. Is it really too much to extend the same level of care to the small number of women for whom such a treatment might buy them a precious few more months with their families? Or do they not count?